64 results about "Multiple Organ Failures" patented technology

Provision of a blood purification system comprising a blood purification tubing and a blood purification apparatus particularly suitable for use in continuous hemofiltration in which in the treatment of a patient with renal disease, multiple organ failure, and the like, the amount of water removed from the patient and the amount of supply to the patient can be more accurately controlled, and in which preparation operation is easy. A blood purification system comprising a blood purification tubing and a blood purification apparatus wherein the soft tubes of flow paths connecting a first planar panel and a second planar panel, and the location of the soft tubes are selected to satisfy a formula of a predetermined condition.

Provision of a blood purification system comprising a blood purification tubing and a blood purification apparatus particularly suitable for use in continuous hemofiltration in which in the treatment of a patient with renal disease, multiple organ failure, and the like, the amount of water removed from the patient and the amount of supply to the patient can be more accurately controlled, and in which preparation operation is easy. A blood purification system comprising a blood purification tubing and a blood purification apparatus wherein the soft tubes of flow paths connecting a first planar panel and a second planar panel, and the location of the soft tubes are selected to satisfy a formula of a predetermined condition.

The present invention relates to 5-thia-omega-substituted phenylprostaglandin E derivatives of the formula (I)(wherein, all the symbols are as defined in the specification), process for producing them and pharmaceutical compositions comprising them as active ingredient.The compounds of the formula (I) can bind to PGE2 receptors (especially, subtype EP4) strongly, so they are expected to be useful for prevention and / or treatment of immunological diseases (autoimmune diseases such as amyotrophic lateral sclerosis (ALS), multiple sclerosis, Sjoegren's syndrome, chronic rheumarthrosis and systemic lupus erythematosus etc., and rejection after organ transplantation etc.), asthma, abnormal bone formation, neuronal cell death, lung failure, liver damage, acute hepatitis, nephritis, renal insufficiency, hypertension, myocardiac ischemia, systemic inflammatory response syndrome, ambustion pain, sepsis, hemophagous syndrome, macrophage activation syndrome, Still's disease, Kawasaki disease, burn, systemic granulomatosis, ulcerative colitis, Crohn's disease, hypercytokinemia at dialysis, multiple organ failure, and shock etc. Further, it is thought that EP4 subtype receptor relates to sleeping disorder and blood platelet aggregation, so the compounds of the present invention are expected to be useful for the prevention and / or treatment of such diseases.

The present invention relates to compounds for treatment that protects the endothelium, prevent pathologic thrombus formation in the microcirculation and preserve platelet number and function and thus may be related to minimizing or preventing development of organ failure, including multiple organ failure (MOF), and, hence, death in critically ill patients by administration of agent(s) limiting the platelets ability to aggregate and form clots and / or by agents modulating / preserving endothelial integrity and / or by agent(s) increasing the rate of thrombus lysis, and Another aspect of the invention related to by a cell-based whole blood viscoelastical haemostatic assay identifying critically ill patients at increased risk of development of organ failure, including multiple organ failure (MOF) and death.

The present invention relates to compounds for treatment that protects the endothelium, prevents pathologic thrombus formation in the microcirculation and preserves platelet number and function and thus may be related to minimizing or preventing development of organ failure, including multiple organ failure (MOF), and, hence, death in critically ill patients by administration of agent(s) limiting the platelets ability to aggregate and form clots and / or by agents modulating / preserving endothelial integrity and / or by agent(s) increasing the rate of thrombus lysis, and Another aspect of the invention related to by a cell-based whole blood viscoelastical haemostatic assay identifying critically ill patients at increased risk of development of organ failure, including multiple organ failure (MOF) and death.

Apparatus, systems and methods for cooling or warming the temperature of all or a portion of the body of a human or animal subject to treat disorders including but not limited to sepsis, septic shock or other inflammatory or infectious conditions which can result in shock, hypoxia, ischemia and / or multiple organ failure in human or animal subjects.

A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its receptor or a soluble receptor that binds to IL-20. Examples of such diseases are adult respiratory disease, psoriasis, eczema, contact dermatitis, atopic dermatitis, septic shock, multiple organ failure, inflammatory lung injury, bacterial pneumonia, inflammatory bowel disease, rheumatoid arthritis, asthma, ulcerative colitis and Crohn's disease.

A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its receptor or a soluble receptor that binds to IL-20. Examples of such diseases are adult respiratory disease, psoriasis, eczema, contact dermatitis, atopic dermatitis, septic shock, multiple organ failure, inflammatory lung injury, bacterial pneumonia, inflammatory bowel disease, rheumatoid arthritis, asthma, ulcerative colitis and Crohn's disease.

Disclosed are: a prognosis diagnosis method which can diagnose the prognosis of a patient suffering from sepsis or sepsis-related multiple organ failure in a simple manner and with high accuracy and a prognosis diagnosis kit for use in the prognosis diagnosis method. The prognosis diagnosis method comprises: a first detection step of detecting a liver fatty acid-binding protein contained in urine collected from a subject with a specific antibody; a second detection step of treating the urine with a Redox reagent such as hemin and detecting a liver fatty acid-binding protein contained in the treated urine with the specific antibody; and a comparison step of comparing a detection value obtained in the first step with a detection value obtained in the second step. It is determined that the larger the detection value obtained in the second step compared to that in the first step, the worse the prognosis.

The present invention discloses a kind of Chinese medicine composition of effective components for supplementing qi and restoring pulse, and belongs to the field of medicine preparing technology. The medicine composition is prepared with total ginsenoside and total dogwood glycoside in certain weight ratio. The medicine composition has the functions of invigorating primodial qi, astringing qi, restoring pulse, etc. and is suitable for treating shock caused by different causes, multiple organ failure, coronary heart disease, etc.

The present invention relates to a use of a pharmaceutical composition in the manufacture of medicament for treating related diseases caused by endotoxemia. The pharmaceutical composition comprises 3-methyl-1-phenyl-2-pyrazolin-5-one or pharmaceutically acceptable salt thereof and borneol. The diseases include, but are not limited to, systemic inflammatory response syndrome, sepsis, severe sepsis, septic shock, sepsis related disseminated intravascular coagulation, acute lung injury, acute respiratory distress syndrome, multiple organ failure syndrome, septic brain injury and inflammatory lung injury caused by other reasons, including but not limited to bacterial pneumonia.

The present invention relates to process for controlling water and electrolyte balance and acid-base equilibrium, and particularly to process for controlling water and electrolyte balance and acid-base equilibrium supervening metabolic acidosis due to burn injury, hemorrhagic shock, multiple organ failure, systemic inflammatory response syndrome (SIRS), and so on. By administering the preparation containing sodium bicarbonate as an alkalizing agent of the present invention, the acidosis correction effect is exhibited immediately after the start of the infusion and disappeared quickly by demedication. And therefore, the preparation of the present invention can be administered safely without inducing metabolic alkalosis during infusion and alkalosis after the infusion. The preparation of the present invention also has no problem with hypernatremia. The controlling water and electrolyte balance and acid-base equilibrium, and particularly to process for controlling water and electrolyte balance can be done by administering the preparation containing bicarbonate at a rate of 2 to 60 mL / kg / hour.

The invention discloses an extracorporeal circulation life supporting device used for treating and curing multiple organ failure. The extracorporeal circulation life supporting device comprises an extracorporeal circulation pipeline which is connected between a vein or artery outlet end of a patient and a vein blood inlet end of the patient; a heparin pump, a first blood pump and a second blood pump are arranged on the extracorporeal circulation pipeline in turn; the extracorporeal circulation pipeline is branched into a first branch and a second branch between the first blood pump and the second blood pump; an oxygen combiner is arranged on the first branch; the second branch extends from the second blood pump which is provided with a blood clamp, a plasma separator, an active carbon jar and a resin jar are arranged at the lower edge of the second blood pump; the plasma outputted from a side wall of the plasma separator enters into the active carbon jar and the resin jar and enters into a blood filter together with the blood cells outputted from an outlet end of the plasma separator; the blood is purified and is applied to a supporting device for curing renal failure; all the branches are converged and enter into the body of the patient from the vein end. According to the extracorporeal circulation life supporting device, one device is used for independently or jointly supporting / replacing the heart, lung, liver and renal function failure.

The invention relates to a formula of a blood filtration replacement fluid which is special for citrate anticoagulation, a preparation method and a usage thereof. With the components of sodium citrate, sodium chloride, potassium chloride, sodium lactate, citric acid and so on, the replacement fluid is mainly used for blood filtration and blood dialysis filtration of the patients with acute renal failure or high risk bleeding due to multiple organ failure etc., and can solve the problems of easy occurrence of hypernatremia and alkali poisoning in the prior citrate anticoagulation, thus facilitating the clinical usage. The replacement fluid has the advantages of strong applicability, exact efficacy and low toxicity and side effects; the preparation process is simple; the quality is stable, safe and effective; the feasibility is strong; the repeatability is high; and the replacement fluid is applicable to the large-scale production and the promotion of the clinical application, thus being the ideal blood filtration replacement fluid for blood filtration, blood dialysis filtration, continuous renal replacement therapy and so on. The demand of the blood dialysis increases along with the increasing number of the patients with the end-stage renal failure year by year, so the blood filtration replacement fluid can generate more tremendous economic and social benefits.

The pharmaceutical composition comprising the compound of the invention having 8-azaprostaglandin skeleton represented by formula (I)(wherein, all the symbols have the same meanings as that of the specification) a salt thereof, a solvate thereof or a cyclodextrin clathrate thereof, or a prodrug thereof and them as active ingredient have EP4 agonistic action and thus are considered useful for the prevention and / or treatment of immunological diseases, asthma, neuronal cell death, arthritis, lung failure, pulmonary fibrosis, pulmonary emphysema, bronchitis, chronic obstructive pulmonary disease, liver damage, acute hepatitis, nephritis, renal insufficiency, hypertension, myocardial ischemia, systemic inflammatory response syndrome, sepsis, hemophagous syndrome, macrophage activation syndrome, Still's disease, Kawasaki disease, burn, systemic granulomatosis, ulcerative colitis, Crohn's disease, hypercytokinemia at dialysis, multiple organ failure, shock and glaucoma, etc. Furthermore, the compounds also have an action of accelerating bone formation, so it is expected to be useful for the prevention and / or treatment of diseases associated with loss in bone mass, for example, primary osteoporosis, secondary osteoporosis, bone metastasis of cancer, hypercalcemia, Paget's disease, bone loss, osteonecrosis, bone formation after bone operation, alternative treatment for bone grafting.

Compounds represented by formula (I), prodrugs thereof and salts thereof, and pharmaceutical compositions comprising the same as an active ingredient (wherein each symbol has the meaning as defined in the specification.).Because of having an EDG-1 agonism, the compounds represented by formula (I) are useful in preventing and / or treating peripheral arterial disease such as arteriosclerosis obliterans, thromboangiitis obliterans, Buerger's disease or diabetic neuropathy, sepsis, angiitis, nephritis, pneumonia, stroke, myocardial infarction, edematous state, atherosclerosis, varicosity such as hemorrhoid, anal fissure or fistula ani, dissecting aneurysm of the aorta, angina, DIC, pleuritis, congestive heart failure, multiple organ failure, bedsore, burn, chronic ulcerative colitis, Crohn's disease, heart transplantation, renal transplantation, dermal graft, liver transplantation, osteoporosis, pulmonary fibrosis, interstitial pneumonia, chronic hepatitis, liver cirrhosis, chronic renal failure, or glomerular sclerosis.

Disclosed is a pulmonary artery catheter (“PAC”) that is used in determining myocardial oxygen consumption. Myocardial oxygen consumption is of critical importance because decreased myocardial energy utilization during acute illness may lead to tissue hypoperfusion, multiple organ failure, and eventually death. The inventor has discovered that myocardial oxygen consumption is a function of the difference in oxygen levels in atrial and mixed venous blood. The invention has further discovered that differences in lactate, glucose or any other measurable blood concentration metabolite in atrial or superior vena cava and mixed venous blood can also be used in determining myocardial oxygen consumption.

Compounds represented by formula (I), prodrugs thereof and salts thereof, and pharmaceutical compositions comprising the same as an active ingredient (wherein each symbol has the meaning as defined in the specification.). Because of having an EDG-1 agonism, the compounds represented by formula (I) are useful in preventing and / or treating peripheral arterial disease such as arteriosclerosis obliterans, thromboangiitis obliterans, Buerger's disease or diabetic neuropathy, sepsis, angiitis, nephritis, pneumonia, stroke, myocardial infarction, edematous state, atherosclerosis, varicosity such as hemorrhoid, anal fissure or fistula ani, dissecting aneurysm of the aorta, angina, DIC, pleuritis, congestive heart failure, multiple organ failure, bedsore, burn, chronic ulcerative colitis, Crohn's disease, heart transplantation, renal transplantation, dermal graft, liver transplantation, osteoporosis, pulmonary fibrosis, interstitial pneumonia, chronic hepatitis, liver cirrhosis, chronic renal failure, or glomerular sclerosis.

[Object] To provide a substituted cycloalkene derivative having an action to suppress intracellular signal transduction or cell activation induced by endotoxin and to suppress cell responses due to the intracellular signal transduction and cell activation such as an excess generation of inflammatory mediators such as TNF-α, pharmacologically acceptable salts therefor, a medicament containing them as an active ingredient, a preparation method therefor, and a medicament containing the aforementioned substituted cycloalkene derivative as an active ingredient which is superior in prophylaxis and / or treatment of diseases such as sepsis (septic shock, disseminated intravascular coagulation, multiple organ failure and the like), that are associated with intracellular signal transduction or cell activation induced by endotoxin and to cell responses to the intracellular signal transduction and cell activation.[Solution] A compound represented by the general formula (I):{whereinX and Y represent a group in which X and Y together with a carbon atom to which they are bound form ring A (the ring is 3- to 7-membered heterocyclyl ring or 3- to 7-membered cycloalkyl ring), each represents a hydrogen atom, or X and Y together represent a substituent of ring B.l and m, independently from each other, represent an integer of 0 to 3, and l+m is 1 to 3.R1 is an aliphatic hydrocarbon group and the like which may be substituted with a group selected from Substituent group β and Substituent group γ. n represents an integer of 0 to 3.R2 is a C1-C6 alkyl group and the like which may be substituted with a group selected from a hydrogen atom and Substituent group β.R3 is a phenyl group, 5- to 6-membered heteroaryl group and the like which may be substituted with a group selected from Substituent group ε.R5 is a C1-C6 alkyl group and the like which may be substituted with a group selected from a hydrogen atom and Substituent group β.Provided that in the case where R3 is a phenyl group which may be substituted with a group selected from Substituent group ε, X and Y represent a group in which X and Y together with a carbon atom to which they are bound form ring A, or X and Y together represent a substituent of ring B.

This invention relates to a medicine for humans, and particularly to a pharmaceutical combination comprising Epidermal Growth Factor (EGF) and Growth Hormone secretagogue hexapeptide (GHRP) for use in preventing tissue damage due to blood flow suppression by enhancing tissue repair following ischemic damage. The aforementioned combination may be applied as a single pharmaceutical composition. Alternatively, an individual may also receive both EGF and GHRP in a separate manner but within a single therapeutic regime to enhance cellular survival when organs are subjected to blood flow deprivation for a critical period of time. This combination attenuates reactive oxygen species (ROS) formation and its associated cytotoxicity. It is also useful in promoting cellular survival when tissue or organs are exposed to prolonged ischemic periods. The combination is useful as a prophylactic agent in those subjects prone to multiple organ failure (MOF) such as burn victims, multiple trauma patients, hypoxic neonates, acute respiratory distress syndrome patients, and necrotizing enterocolitis patients.

A BH4 fusion polypeptide comprising an amino acid sequence of a polypeptide capable of exhibiting uptake action into a cell or a derivative sequence thereof; and an amino acid sequence selected from the group consisting of (A) an amino acid sequence comprising at least the sequence of BH4 domain (SEQ ID NO: 1) of anti-apoptotic Bcl-2 family protein, (B) an amino acid sequence having substitution, deletion or insertion of at least one amino acid residue in the amino acid sequence of SEQ ID NO: 1, and (C) an amino acid sequence having at least 50% sequence identity to the amino acid sequence of SEQ ID NO: 1, wherein the BH4 fusion polypeptide is capable of inhibiting apoptosis; an apoptosis-inhibitor comprising the BH4 fusion polypeptide mentioned above; a method for treating an ischemic disease, characterized by administering the apoptosis-inhibitor mentioned above to a patient with the ischemic disease to inhibit apoptosis, thereby treating the ischemic disease; and use of the BH4 polypeptide mentioned above, for manufacturing a prophylactic or therapeutic agent for an ischemic disease. According to the present invention, the apoptosis can be efficiently suppressed, so that its application as a therapeutic agent for AIDS, neurodegenerative disorders, osteomyelodysplasia, ischemic diseases, infectious multiple organ failure, fulminant hepatitis, diabetes and the like can be expected.

The present invention discloses one kind of lipopolysaccharide bindin and its monoclonal antibody, preparation process and use. Through extracting NH-LBP coding cDNA segment from human liver cell, preparing NH-LBP protein with insect sf21 cell, establishing humanized phage antibody base with pComb3H phagemid and screening with NH-LBP as antigen, anti-NH-LBP humanized monoclonal antibodies, Fab antibody and dsFv antibody are prepared. The Fab antibody and the dsFv antibody can combine specifically with the N end of complete human lipopolysaccharide bindin and inhibit the combination between LBP and LPS competively to lower the LPS sensitivity of body, lower LPS caused excessive inflammatory reaction, promote the degradation of LPS in body and prevent diffused blood coagulation inside capillary vessel and multiple organ failure.

The present invention relates to use an agent for the prevention and / or treatment of multiple organ dysfunction syndrome (MODS) or multiple organ failure (MOF) comprising interleukin-22 (IL-22) as an effective ingredient. The present invention is applicable to prevention of or therapy for diseases from sepsis, septic shock, liver failure, to multiple organ dysfunction syndromes. More particularly, the present invention is useful for an emergency medical service, for treatment of injury caused by a traffic accident, burns, heat attacks, hypercytokinemia or severe infective diseases.

The present invention relates to use an agent for the prevention and / or treatment of multiple organ dysfunction syndrome (MODS) or multiple organ failure (MOF) comprising interleukin-22 (IL-22) as an effective ingredient. The present invention is applicable to prevention of or therapy for diseases from sepsis, septic shock, liver failure, to multiple organ dysfunction syndromes. More particularly, the present invention is useful for an emergency medical service, for treatment of injury caused by a traffic accident, burns, heat attacks, hypercytokinemia or severe infective diseases.

A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, which can be either a peptide or a peptide mimetic, said preparation being useful for treatment and prophylaxis of disorders of the alimentary tract, such as dyspepsia, irritable bowel syndrome and multiple organ failure. Use of an angiotensin II type 2 receptor agonist for the manufacture of a medicament for treatment and / or prophylaxis of disorder of the alimentary tract, such as dyspepsia, irritable bowel syndrome and multiple organ failure. A method for treatment and / or prevention of a condition selected from the group consisting of disorders of the alimentary tract, such as dyspepsia, irritable bowel syndrome and multiple organ failure in a patient, wherein an effective amount of an angiotensin II type 2 receptor agonist is administered to the patient.

The present invention discloses a kind of qi supplementing and pulse-recovering Chinese medicine injection and its preparation process, and belongs to the field of medicine preparing technology. The Chinese medicine injection is prepared with Chinese medicinal materials ginseng, ophiopogon root and dogwood in certain weight proportion, and through first extraction to obtain intermediate and the subsequent preparation into injection, transfused liquid or freeze dried powder for injection. The Chinese medicine injection is used in treating shock caused by different causes, multiple organ failure, coronary heart disease and other cardiac and cerebral vascular diseases, and may be also used for auxiliary treatment of cancer and diabetes.

A compound of formula (I)Wherein X, Y, ring A, ring B, l, m, R1, R2, R4 and R5 are as defined herein, to supress intracellular signal transduction or cell activation induced by endotoxin and to suppress cell responses due to the intracellular signal transduction and cell activation such as an excess generation of inflammatory mediators such as TNF-α, pharmacologically acceptable salts therefor, a preparation method therefor, and a medicament containing the aforementioned substituted cycloalkene derivative as an active ingredient which is superior in prophylaxis and / or treatment of diseases such as sepsis (septic shock, disseminated intravascular coagulation, multiple organ failure and the like), that are associated with intracellular signal transduction or cell activation induced by endotoxin and to cell responses to the intracellular signal transduction and cell activation.